Circadian Adaptive DBS in Essential Tremor
Recruiting now · Not applicable
Conditions studied: Essential Tremor, Essential Tremor (ET), Essential Tremor, Movement Disorders
In brief
Deep brain stimulation (DBS) of the thalamus is an effective treatment for medically refractory essential tremor (ET). DBS involves delivering continuous stimulation to the brain through electrodes permanently implanted in the thalamus. Despite proven effectiveness, the long-term benefit of DBS can wane over time (habituation) and side effects, including paresthesia and dysarthria, often limit the amplitude of the stimulation, resulting in suboptimal control of tremor. In clinical practice, many groups advise patients to switch their devices off at night to avoid habituation and reduce side effects. However, manually turning off the device at night can result in uncontrolled tremor when the patient moves at night. This study aims to develop an algorithm that automatically turns off stimulation when a patient is asleep, based on circadian brain signals. Turning off stimulation could potentially improve the therapy by limiting adverse effects, increasing efficacy, reducing the risk of habituation, and prolonging battery life. This study will evaluate the feasibility, safety, and tolerability of circadian adaptive DBS.
Key facts
- Study ID
- NCT06635811
- Run by
- University of Florida
- People needed
- 25
- Starts
- 2025-05-01
- Expected to finish
- 2029-10-01
- Last updated by the study team
- 2026-07-30
Who can join
Age: 21 and older, up to 89. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of Essential Tremor confirmed by a Movement Disorders specialist following established criteria recommended by the Movement Disorders Society
- Patients implanted with unilateral or bilateral VIM DBS leads attached to the Medtronic Percept DBS device for the treatment of Essential Tremor
- Patients with clinical benefit of DBS as defined by a 30% improvement on the TRS or TETRAS at least 3 months after DBS implantation
- DBS programmed in a monopolar configuration allowing chronic brain sensing (C+1- or C+2- in ring mode or any direction)
- Be between 21 and 89 years old
- Ability to give informed consent for the study
You may not qualify if…
- Inability to comply with the study protocol
- Pregnancy: all women of childbearing potential will have a negative urine pregnancy test prior to undergoing the study
- Current active suicidal ideation (Yes to #2-5 on C-SSRS)
- Any personality or mood symptoms that study personnel believe will interfere with study requirements
Where it is running
- Norman Fixel Institute for Neurological Diseases — Gainesville, Florida, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.